Laboratory of America Holdings (Laboratory of America Holdings) COGS-to-Revenue

: 0.73 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Laboratory of America Holdings's Cost of Goods Sold for the three months ended in Dec. 2023 was $2,212 Mil. Its Revenue for the three months ended in Dec. 2023 was $3,033 Mil.

Laboratory of America Holdings's COGS to Revenue for the three months ended in Dec. 2023 was 0.73.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Laboratory of America Holdings's Gross Margin % for the three months ended in Dec. 2023 was 27.08%.

Laboratory of America Holdings COGS-to-Revenue Historical Data

The historical data trend for Laboratory of America Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratory of America Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.72

0.65

0.62

0.69

0.72

Laboratory of America Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.73	0.74	0.72	0.72	0.73

Laboratory of America Holdings COGS-to-Revenue Calculation

Laboratory of America Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8796.7	/	12161.6
	=	0.72

Laboratory of America Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2211.9	/	3033.3
	=	0.73

Laboratory of America Holdings (NYSE:LH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Laboratory of America Holdings's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2211.9 / 3033.3
	=	27.08 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Laboratory of America Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

LH:Mexico L1CA34:Brazil

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney	officer: SVP, Chief Medical Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams	director	DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215